©The Author(s) 2025.
World J Hepatol. Sep 27, 2025; 17(9): 110049
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.110049
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.110049
Table 6 Multivariate linear regression analysis of albumin-bilirubin score and other non-invasive tests for predicting liver fibrosis
| Model | Unstandardized coefficients B | SE | Standardized coefficients beta | t | P value | 95%CI |
| Constant | 1.788 | 0.180 | 9.911 | < 0.001 | 1.433-2.144 | |
| ALBI | 0.212 | 0.054 | 0.257 | 3.936 | < 0.001 | 0.106-0.318 |
| AST to ALT | 0.103 | 0.094 | 0.069 | 1.092 | 0.276 | -0.083 to 0.288 |
| APRI score | 0.136 | 0.044 | 0.229 | 3.077 | 0.002 | 0.049-0.222 |
| FIB-4 index | 0.007 | 0.012 | 0.045 | 0.610 | 0.543 | -0.017 to 0.031 |
- Citation: Ewid M, Sherif H, Saquib N, Alammari AM, Ismail AAM, Alkahlot MH, Ahmed ZT, Al-Zabidi FZM, Al Mutiri N. Albumin-bilirubin score reflects the extent of liver fibrosis in chronic hepatitis C patients treated with direct-acting antivirals. World J Hepatol 2025; 17(9): 110049
- URL: https://www.wjgnet.com/1948-5182/full/v17/i9/110049.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i9.110049